---
layout: post
title: "Advancing the Development of Therapeutics Through Rare Disease Patient Community Engagement"
date: 2026-02-05 18:57:37 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-25500
original_published: 2023-11-20 00:00:00 +0000
significance: 8.00
---

# Advancing the Development of Therapeutics Through Rare Disease Patient Community Engagement

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** November 20, 2023 00:00 UTC
**Document Number:** 2023-25500

## Summary

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Advancing the Development of Therapeutics Through Rare Disease Patient Community Engagement." Convened by the Duke-Robert J. Margolis, MD Center for Health Policy (Duke-Margolis) in collaboration with FDA and supported by a cooperative agreement between FDA and Duke-Margolis, the workshop will focus on how best to understand patients' experiences living with a rare disease and how to incorporate those experiences, as well as patients' priorities for treatment goals, throughout the drug development process.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/11/20/2023-25500/advancing-the-development-of-therapeutics-through-rare-disease-patient-community-engagement)
- API: https://www.federalregister.gov/api/v1/documents/2023-25500

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
